HOME >> BIOLOGY >> NEWS
U-M scientist finds molecule plants use to control early cell development

U-M scientist finds protein signal and receptor molecule plants use to control early cell development. Similar structures common in animal cells.

University of Michigan scientist Steven Clark has taken a major step toward understanding one of life's oldest mysteries--how genes work together in plants to turn generic cells into specialized cells destined to become leaves, stems or flowers.

The first identification of such a mechanism in plants is reported by Clark and his research associates in the July 28 issue of Science. It is a protein ligand-receptor pair--a common cell signaling technique used by animals from roundworms to humans to control transformations from unspecialized stem cells to specialized organ cells.

In addition to its significance for basic science, the discovery could have important applications in agriculture, according to Clark, an associate professor of biology at the U-M, who is affiliated with the U-M's Center for Organogenesis. Clark says researchers could use genetic engineering technology to increase flower and fruit production, or to control the timing of fruit development.

Clark works with Arabidopsis, a plant often used to study plant genetics and development. In the Science paper, he explains how an Arabidopsis gene called CLAVATA3 encodes a small protein signal called a ligand, which hangs out near patches of unspecialized plant cells called meristems. Another gene, CLAVATA1, encodes a receptor molecule, which penetrates meristem cell walls, with half the receptor on the outside and half inside the cell membrane.

When the ligand binds to the outer half of the receptor, it triggers chemical changes inside the meristem cell. A series of messenger molecules carry these chemical signals to genes in the cell nucleus telling them to turn off the locking signal that keeps meristem cells from developing. Once the locking signal stops, the meristem begins forming a tiny plant shoot, which will grow
'"/>

Contact: Sally Pobojewski
pobo@umich.edu
734-647-1844
University of Michigan
26-Jul-2000


Page: 1 2

Related biology news :

1. EMBO Gold Medal 2004 goes to Spanish scientist
2. DNA lends scientists a hand, revealing new chemical reactions
3. UCSF scientist Joe Derisi named MaCarthur Fellow
4. Conference at UH opens doors for new scientists, engineers
5. Wisconsin scientists develop quick botox test
6. UCI scientists successfully target key HIV protein; breakthrough may lead to new drug therapies
7. Alaska scientists find Arctic tundra yields surprising carbon loss
8. DuPont scientist named one of the worlds top young innovators by MITs Technology Review Magazine
9. UAF scientists discover new marine habitat in Alaska
10. Information system to help scientists analyze mechanisms of social behavior
11. White House to honor UNC School of Medicine scientist for early career achievement

Post Your Comments:
(Date:5/14/2015)... , May 14, 2015 Research and Markets ... of the "Fingerprint Sensors Market in Smart Mobile ... This report believes that 2014 was a watershed year ... Apple,s introduction of ,Apple Pay,. Apple gave fingerprint sensors ... mobile payment service. Fingerprint sensors are a must-have feature ...
(Date:5/11/2015)... DAYTON, Ohio , May 11, 2015  Through a ... Ohio had a strong showing at AUVSI,s ... . These representatives of Ohio,s UAS ... domestic and abroad from all points along the UAS ecosystem. ... Dayton Development Coalition,s (DDC) Vice President for Aerospace Rich ...
(Date:5/8/2015)... May 8, 2015 Synaptics Inc. (NASDAQ: SYNA ... that members of the executive management team will present at ... Technology, Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company ... 2:45pm ET Location: The New York Palace Hotel, ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Synaptics to Present at Upcoming Investor Conferences 2
(Date:5/21/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... develops and commercializes proprietary technologies and products for advanced ... for the second fiscal quarter ended March 31, 2015. ... to advance business with our existing customers and to ... and CEO of SQI. "The delivery of a fully ...
(Date:5/21/2015)... San Francisco, CA (PRWEB) May 21, 2015 ... microbiome sequencing, has announced a partnership with PicnicHealth, ... records for patients. Participants diagnosed with Inflammatory Bowel ... as well as a complementary uBiome research kit. ... Summer 2014. , For more ...
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... 2015 Tunnell Consulting, Inc. ... as senior statistician and Principal, a position to which ... the management and analysis of complex and large data ... , “We’re delighted to have Julia join the Tunnell ... said Dr. Philippe Cini, Group Vice President and leader ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
Cached News: